Nuvation Bio: Judgement Day Grows Closer

2025-06-10 15:19:33 ET

Shares of cancer therapy concern Nuvation Bio, Inc. ( NUVB ) are down over 75% since their debut in 2021 as none of the biotech’s initial lineup of therapies made it past Phase 1 evaluation. Its 2024 purchase of AnHeart has provided it with a NSCLC therapy (taletrectinib) recently approved in China with a June 23, 2025 PDUFA date in the U.S. plus a viable glioma candidate. Owning a ROS1+ NSCLC asset with a superior efficacy profile to approved therapies but in an indication with a small current market, this busted IPO merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: